Interleukin‑6 as a potential molecular target in esophageal squamous cell carcinoma

Zhao,Zhi‑Fei; Li,Jian‑Xiong; Ye,Rui; Wu,Xuan; Gao,Ling‑Ling; Niu,Bao‑Long

doi:10.3892/ol.2015.3990

Interleukin‑6 as a potential molecular target in esophageal squamous cell carcinoma

Authors:
- Zhi‑Fei Zhao
- Jian‑Xiong Li
- Rui Ye
- Xuan Wu
- Ling‑Ling Gao
- Bao‑Long Niu
View Affiliations

Affiliations: Department of Radiotherapy, General Hospital of PLA, Beijing 100853, P.R. China
Published online on: December 3, 2015 https://doi.org/10.3892/ol.2015.3990
Pages: 925-932
Copyright: © Zhao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Knowledge of potential tumor markers may improve chemotherapeutic efficacy. Interleukin‑6 (IL‑6) expression in local tumor tissues is associated with cancer progression and poor prognosis in variety of cancer types. The aim of the present study was to investigate the role and potential application of IL‑6 in determining the prognosis of esophageal carcinoma. KYSE170 and TE13 esophageal cancer cell lines were used to conduct cell‑ and animal‑based experiments investigating biological changes and tumor behavior. Immunohistochemical analysis revealed that 70‑80% of cancer cells exhibited positive staining for IL‑6, compared with <15% of non‑malignant epithelial cells. These immunohistochemical results were consistent with the mRNA expression levels detetced. The IL‑6 silencing vector significantly reduced invasion and proliferation of the two cell lines and attenuated tumor growth in xenograft mouse models (P<0.05). The IL‑6 silencing vector markedly reduced the presence of Ki‑67 (a typical proliferation marker) and microvessel density, indicating that downregulation of IL‑6 levels may greatly affect tumor growth and inhibition. The IL‑6 silencing vector increased E‑cadherin and matrix metalloproteinase (MMP)‑9 expression levels in the two esophageal carcinoma cell lines. This vector also regulated the release of IL‑6 in cell supernatant and serum in KYSE170‑ and TE13‑tumor‑bearing mice. The secretion of vascular endothelial growth factor and cluster of differentiation 31 (a nuclear protein) immunoreactive molecules were also reduced by the IL‑6 silencing vector. Therefore, IL‑6 may be an important trigger in the progression of angiogenesis and endothelial tube formation within the tumor, and targeting IL‑6 may be a promising strategy for the treatment of esophageal cancer.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
2	Sarwar Shahbaz CM, Luketich JD, Landreneau RJ and Abbas G: Esophageal cancer, An update. Int J Surg. 8:417–422. 2010. View Article : Google Scholar : PubMed/NCBI
3	Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249. 2009. View Article : Google Scholar : PubMed/NCBI
4	Allum WH, Stenning SP, Bancewicz J, Clark PI and Langley RE: Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol. 27:5062–5067. 2009. View Article : Google Scholar : PubMed/NCBI
5	Sjoquist KM, Burmeister BH, Smithers BM, Zalcberg JR, Simes RJ, Barbour A and Gebski V: Australasian Gastro-Intestinal Trials Group: Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma. An updated meta-analysis. Lancet Oncol. 12:681–692. 2011. View Article : Google Scholar : PubMed/NCBI
6	Chen WQ, Zheng RS, Zhang SW, Li N, Zhao P, Li GL, Wu LY and He J: Report of incidence and mortality in china cancer registries, 2008. Chin J Cancer Res. 24:171–180. 2012. View Article : Google Scholar : PubMed/NCBI
7	Liu Q, Li R, Zhu Z, Qian X, Guan W, Yu L, Yang M, Jiang X and Liu B: Enhanced antitumor efficacy, biodistribution and penetration of docetaxel-loaded biodegradable nanoparticles. Int J Pharm. 430:350–358. 2012. View Article : Google Scholar : PubMed/NCBI
8	Coussens LM and Werb Z: Inflammation and cancer. Nature. 420:860–867. 2002. View Article : Google Scholar : PubMed/NCBI
9	Balkwill F and Mantovani A: Inflammation and cancer: Back to Virchow? Lancet. 357:539–545. 2001. View Article : Google Scholar : PubMed/NCBI
10	Gonda TA, Tu S and Wang TC: Chronic inflammation, the tumor microenvironment and carcinogenesis. Cell Cycle. 8:2005–2013. 2009. View Article : Google Scholar : PubMed/NCBI
11	Abdel-Latif MM, Duggan S, Reynolds JV and Kelleher D: Inflammation and esophageal carcinogenesis. Curr Opin Pharmacol. 9:396–404. 2009. View Article : Google Scholar : PubMed/NCBI
12	Schafer ZT and Brugge JS: IL-6 involvement in epithelial cancers. J Clin Invest. 117:3660–3663. 2007. View Article : Google Scholar : PubMed/NCBI
13	Akira S, Taga T and Kishimoto T: Interleukin-6 in biology and medicine. Adv Immunol. 54:1–78. 1993. View Article : Google Scholar : PubMed/NCBI
14	Chen CC, Chen WC, Lu CH, Wang WH, Lin PY, Lee KD and Chen MF: Significance of interleukin-6 signaling in the resistance of pharyngeal cancer to irradiation and the epidermal growth factor receptor inhibitor. Int J Radiat Oncol Biol Phys. 76:1214–1224. 2010. View Article : Google Scholar : PubMed/NCBI
15	Santer FR, Malinowska K, Culig Z and Cavarretta IT: Interleukin-6 trans-signalling differentially regulates proliferation, migration, adhesion and maspin expression in human prostate cancer cells. Endocr Relat Cancer. 17:241–253. 2010. View Article : Google Scholar : PubMed/NCBI
16	Kishimoto T: Interleukin-6:F rom basic science to medicine - 40 years in immunology. Annu Rev Immunol. 23:1–21. 2005. View Article : Google Scholar : PubMed/NCBI
17	Guo Y, Xu F, Lu T, Duan Z and Zhang Z: Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev. 38:904–910. 2012. View Article : Google Scholar : PubMed/NCBI
18	Stahl M: Is there any role for surgery in the multidisciplinary treatment of esophageal cancer? Ann Oncol. 21((Suppl 7)): vii283–vii285. 2010.PubMed/NCBI
19	Trikha M, Corringham R, Klein B and Rossi JF: Targeted anti-interleukin-6 monoclonal antibody therapy for cancer, A review of the rationale and clinical evidence. Clin Cancer Res. 9:4653–4665. 2003.PubMed/NCBI
20	Leu CM, Wong FH, Chang C, Huang SF and Hu CP: Interleukin-6 acts as an antiapoptotic factor in human esophageal carcinoma cells through the activation of both STAT3 and mitogen-activated protein kinase pathways. Oncogene. 22:7809–7818. 2003. View Article : Google Scholar : PubMed/NCBI
21	Chen MF, Lee KD, Lu MS, Chen CC, Hsieh MJ, Liu YH, Lin PY and Chen WC: The predictive role of E2-EPF ubiquitin carrier protein in esophageal squamous cell carcinoma. J Mol Med (Berl). 87:307–320. 2009. View Article : Google Scholar : PubMed/NCBI
22	Thiery JP: Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2:442–454. 2002. View Article : Google Scholar : PubMed/NCBI
23	Scott DW and Gascoyne RD: The tumour microenvironment in B cell lymphomas. Nat Rev Cancer. 14:517–534. 2014. View Article : Google Scholar : PubMed/NCBI
24	McConkey DJ, Choi W, Marquis L, Martin F, Williams MB, Shah J, Svatek R, Das A, Adam L, Kamat A, et al: Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer. Cancer Metastasis Rev. 28:335–344. 2009. View Article : Google Scholar : PubMed/NCBI
25	Tartour E, Pere H, Maillere B, Terme M, Merillon N, Taieb J, Sandoval F, Quintin-Colonna F, Lacerda K, Karadimou A, et al: Angiogenesis and immunity: A bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy. Cancer Metastasis Rev. 30:83–95. 2011. View Article : Google Scholar : PubMed/NCBI
26	Sharma S, Sharma MC and Sarkar C: Morphology of angiogenesis in human cancer, A conceptual overview, histoprognostic perspective and significance of neoangiogenesis. Histopathology. 46:481–489. 2005. View Article : Google Scholar : PubMed/NCBI
27	Landskron G, De la Fuente M, Thuwajit C and Hermoso MA: Chronic inflammation and cytokines in the tumor microenvironment. J Immunol Res. 2014:2014. View Article : Google Scholar : PubMed/NCBI
28	Sepúlveda P, Encabo A, Carbonell-Uberos F and Miñana MD: BCL-2 expression is mainly regulated by JAK/STAT3 pathway in human CD34+ hematopoietic cells. Cell Death Differ. 14:378–380. 2007. View Article : Google Scholar : PubMed/NCBI
29	Aggarwal BBA, Kunnumakkara AB, Harikumar KB, Gupta SR, Tharakan ST, Koca C, Dey S and Sung B: Signal transducer and activator of transcription-3, inflammation, and cancer, How intimate is the relationship? Ann N Y Acad Sci. 1171:59–76. 2009. View Article : Google Scholar : PubMed/NCBI
30	Levy DE and Darnell JE Jr: Stats: Transcriptional control and biological impact. Nat Rev Mol Cell Biol. 3:651–662. 2002. View Article : Google Scholar : PubMed/NCBI
31	Bromberg J: Stat proteins and oncogenesis. J Clin Invest. 109:1139–1142. 2002. View Article : Google Scholar : PubMed/NCBI
32	Bishop JL, Thaper D and Zoubeidi A: The multifaceted roles of STAT3 signaling in the progression of prostate cancer. Cancers (Basel). 6:829–859. 2014. View Article : Google Scholar : PubMed/NCBI
33	Chen MF, Lu MS, Lin PY, Chen PT, Chen WC and Lee KD: The role of DNA methyltransferase 3b in esophageal squamous cell carcinoma. Cancer. 118:4074–4089. 2012. View Article : Google Scholar : PubMed/NCBI
34	Sarvaiya PJ, Guo D, Ulasov I, Gabikian P and Lesniak MS: Chemokines in tumor progression and metastasis. Oncotarget. 4:2171–2185. 2013. View Article : Google Scholar : PubMed/NCBI
35	Schindler C, Levy DE and Decker T: JAK-STAT signaling, From interferons to cytokines. J Biol Chem. 282:20059–20063. 2007. View Article : Google Scholar : PubMed/NCBI
36	Mian BM, Dinney CP, Bermejo CE, Sweeney P, Tellez C, Yang XD, Gudas JM, McConkey DJ and Bar-Eli M: Fully human anti-interleukin 8 antibody inhibits tumor growth in orthotopic bladder cancer xenografts via down-regulation of matrix metalloproteases and nuclear factor-kappaB. Clin Cancer Res. 9:3167–3175. 2003.PubMed/NCBI